Home » Stocks » MREO

Mereo BioPharma Group PLC (MREO)

Stock Price: $2.99 USD -0.04 (-1.32%)
Updated Jan 26, 2021 4:00 PM EST - Market closed
Pre-market: $3.07 +0.08 (2.68%) Jan 27, 7:06 AM
Market Cap 108.05M
Revenue (ttm) n/a
Net Income (ttm) -45.85M
Shares Out 71.24M
EPS (ttm) -2.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day January 26
Last Price $2.99
Previous Close $3.03
Change ($) -0.04
Change (%) -1.32%
Day's Open 3.07
Day's Range 2.95 - 3.17
Day's Volume 827,803
52-Week Range 0.80 - 3.60

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation
InvestorPlace - 4 weeks ago

Looking for penny stocks to buy? Click for seven that are hot right now and should continue to rise in the future.

Other stocks mentioned: AMRS, CNSP, CYRN, NGD, RARE, XELA
GlobeNewsWire - 1 month ago

Clinical-stage monoclonal antibody in development for rare genetic bone disease that builds on Ultragenyx's existing bone franchise

GlobeNewsWire - 1 month ago

LONDON and REDWOOD CITY, Calif., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc...

GlobeNewsWire - 2 months ago

LONDON and REDWOOD CITY, Calif., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc...

GlobeNewsWire - 2 months ago

LONDON and REDWOOD CITY, Calif., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc...

GlobeNewsWire - 2 months ago

LONDON and REDWOOD CITY, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc...

GlobeNewsWire - 3 months ago

LONDON and REDWOOD CITY, Calif., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) (“Mereo” or “the Company”), a clinical stage biopharmaceutical company foc...

GlobeNewsWire - 3 months ago

On track to initiate Phase 1b/2 basket study of etigilimab in combination with an anti-PD-1 in a series of tumor types in Q4 2020

Seeking Alpha - 3 months ago

Mereo BioPharma's (MREO) CEO Denise Scots-Knight on 2020 Interim Financial Results Conference Call Transcript

GlobeNewsWire - 3 months ago

On track to initiate Phase 1b/2 etigilimab (Anti-TIGIT) combination study in Q4 2020

GlobeNewsWire - 4 months ago

LONDON and REDWOOD CITY, Calif., Sept. 24, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company f...

GlobeNewsWire - 4 months ago

LONDON and REDWOOD CITY, Calif., Sept. 16, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company f...

GlobeNewsWire - 5 months ago

LONDON and REDWOOD CITY, Calif., Aug. 25, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company fo...

GlobeNewsWire - 6 months ago

LONDON and REDWOOD CITY, Calif., June 30, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), “Mereo” or “the Company”, a clinical-stage biopharmaceutical company fo...

GlobeNewsWire - 7 months ago

Operational progress, positioned for clinical milestones in oncology and rare diseases Operational progress, positioned for clinical milestones in oncology and rare diseases

GlobeNewsWire - 7 months ago

Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio Plans to Develop Etigilimab (Anti-TIGIT) Alongside Rare Disease Product Portfolio

GlobeNewsWire - 10 months ago

LONDON and REDWOOD CITY, Calif., March 27, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH) “Mereo” or “the Company”, a clinical-stage biopharmaceutical company fo...

GlobeNewsWire - 11 months ago

LONDON and REDWOOD CITY, Calif., Feb. 19, 2020 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or the "Company," today announced that it has entered into a Se...

GlobeNewsWire - 1 year ago

Additional Data Demonstrate Dose-Dependent Increase in Bone Strength Stiffness and Failure Load at the Radius as Measured by Finite Element Analysis, a Second Prespecified Primary Endpoint, Re...

GlobeNewsWire - 1 year ago

Oncologie receives exclusive global license to develop and commercialize navicixizumab

Seeking Alpha - 1 year ago

Liver Therapy Forum weekly digest provides an overview of what's happening in therapeutics for endocrine disorders in 2019. The focus this week is Mereo BioPharma.

Zacks Investment Research - 1 year ago

Mereo BioPharma has been struggling lately, but the selling pressure may be coming to an end soon.

24/7 Wall Street - 1 year ago

In 2019, the American Cancer Society estimates that about 22,530 women will receive a new diagnosis of ovarian cancer and that about 13,980 women will die from this disease in the United State...

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, acquires, develops, and commercializes therapeutics for the treatment of oncology and rare diseases. Its lead product candidate, etigilimab (OMP-313M32), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumor. The company also develops Navicixizumab (OMP-305B83) that is in Phase 1a clinical trial for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that has completed Phase II ... [Read more...]

Industry
Biotechnology
Founded
2015
CEO
Denise Pollard-Knight
Employees
50
Stock Exchange
NASDAQ
Ticker Symbol
MREO
Full Company Profile

Financial Performance

Financial numbers in millions GBP.
Financial Statements

Analyst Forecasts

According to one analyst, the rating for MREO stock is "Strong Buy" and the 12-month stock price forecast is 8.00.

Price Target
$8.00
Analyst Consensus: Strong Buy